Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
101.60    -1.60 (-1.55%)
Bid:
101.60
Ask:
102.60
Spread: 1.00 (0.984%)
Market Cap: £166.57m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

AGM Statement

22 Oct 2019 07:00

RNS Number : 5705Q
Synthomer PLC
22 October 2019
 

 

 

 

LEI Number: 213800EHT3TI1KPQQJ56

 

Synthomer plc ("the Company") - 2019 AGM voting outcome update statement

 

 

 

In its 2019 AGM results announcement, the Company reported that all resolutions were passed, although there was a significant minority vote against resolution 11 which related to the re-election of Neil Johnson, the Chairman of the Company, as a non-executive director. Total votes received in favour of this resolution were 64.72%.

 

Following the AGM results, the Company has actively sought to engage in dialogue with a number of significant shareholders who voted against Neil's re-election and with a leading proxy voting advisory body. The dialogue was initiated in order to better understand the reasons behind the dissenting votes, which were based on:

 

·; Concerns over Neil's availability to devote sufficient time to carry out his responsibilities as Chairman of the Company ("over boarding"); and

 

·; The absence of a commitment and plan by the Synthomer Board ("the Board") to implement the Hampton-Alexander Review Recommendation of 33% representation of women on the Board by the end of 2020) ("the Recommendation").

 

 

The Board has carefully considered the over boarding' concerns which are understood to arise due to Neil's role as chair of two other public company boards - QinetiQ Group plc (QinetiQ) and Electra Private Equity plc (Electra). Whilst the Board acknowledges that Neil's role as chairman of the QinetiQ board is a significant commitment which should be counted as such this is not however considered to be the case with his chairmanship of Electra. As Electra has publicly stated, it is conducting a managed wind-down of its final few investments and reducing overheads prior to closing the fund which has currently resulted in it having only two employees and requiring minimal input from Neil. Accordingly, the Board strongly believes that Neil is an effective Chairman with sufficient capacity to meet his commitments, and has no concerns over his availability to deal with Company matters.

 

The Board adopted its current policy on diversity in 2014 and has not recommended the setting of quotas for female or other representation. The Board has appointed women to fill the most recent two vacancies that have arisen for independent non-executive directors resulting in female representation of 22.2% on the Board since September 2018. In order to address both the Recommendation and the need for the refreshment of independent non-executive directors over the next 18 months in accordance with the provisions of the UK Corporate Governance Code ("the Code") the Board has decided to commit to the appointment of an additional female independent non-executive director by the end of 2020. Whilst this will increase the size of the Board in the short term to 10 it is expected that the Board will reduce to 9 during the first half of 2021. It should be noted that the Board has two long standing male non independent non-executive directors who are not subject to the tenure requirements of the Code and who each continue to provide a highly valued contribution.

 

The Board will continue to engage with shareholders on these points as required and will set out further details of any such dialogue and relevant justification for the re-election for all members of the Board in the 2020 annual report and accounts and associated documentation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGMBGBDGBSDBGCB
Date   Source Headline
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration
13th Feb 20257:00 amRNSHolding(s) in Company
28th Jan 202510:30 amRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSWinter trading statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.